Reviva Pharmaceuticals (RVPH) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Financial Results for September 30, 2025 Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights – Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – Cupertino, Calif., November 13, ...